不稳定型心绞痛和非ST段抬高型心肌梗死患者的抗血小板治疗:CRUSADE全国质量改进计划的研究结果
Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative.
作者信息
Bottorff Michael B, Nutescu Edith A, Spinler Sarah
机构信息
College of Pharmacy, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA.
出版信息
Pharmacotherapy. 2007 Aug;27(8):1145-62. doi: 10.1592/phco.27.8.1145.
Evidence-based clinical practice guidelines encapsulate current knowledge to guide health care professionals in the treatment of patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTEMI), yet adherence to guideline recommendations is suboptimal. Guideline adherence may be improved by quality improvement programs such as the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation?) National Quality Improvement Initiative of the American College of Cardiology-American Heart Association Guidelines. The CRUSADE data have been analyzed to demonstrate that overall guideline adherence is directly associated with mortality and that improvement in guideline adherence saves lives. Also, the CRUSADE data have determined that the real-life mortality risk associated with unstable angina and NSTEMI is greater than suggested by clinical trials. The newer antiplatelet drugs recommended in early intervention and discharge treatment strategies are underused across many segments of the unstable angina-NSTEMI population. Glycoprotein IIb-IIIa inhibitors are underused in high-risk populations, and clopidogrel is markedly underused in patients who are medically managed rather than undergoing percutaneous coronary intervention or coronary artery bypass graft surgery. In addition, often the specialty of the treating physician and the status of the hospital influence the use of antiplatelet therapy. The reasons for underprescribing of antiplatelet drugs by physicians are not entirely clear but may be related to a lack of guideline familiarity and understanding, as well as factors such as drug novelty, safety, and cost. Continued education and data dissemination are therefore vital in promoting the prescription of guideline-recommended drugs, both in the early hospitalization phase and as patients transition to community-based care. The role of the pharmacist is pivotal in ensuring adherence to clinical guidelines by interacting with both the physician and patient.
循证临床实践指南总结了当前的知识,以指导医护人员治疗不稳定型心绞痛或非ST段抬高型心肌梗死(NSTEMI)患者,然而对指南建议的遵循情况并不理想。通过质量改进项目,如美国心脏病学会-美国心脏协会指南的CRUSADE(不稳定型心绞痛患者能否通过早期实施快速风险分层抑制不良结局?)国家质量改进计划,可能会提高对指南的遵循程度。对CRUSADE数据进行分析后表明,总体上对指南的遵循与死亡率直接相关,并且提高对指南的遵循程度可挽救生命。此外,CRUSADE数据还确定,与不稳定型心绞痛和NSTEMI相关的实际死亡率风险高于临床试验所提示的风险。在不稳定型心绞痛-NSTEMI人群的许多亚组中,早期干预和出院治疗策略中推荐的新型抗血小板药物未得到充分使用。糖蛋白IIb-IIIa抑制剂在高危人群中未得到充分使用,而氯吡格雷在接受药物治疗而非接受经皮冠状动脉介入治疗或冠状动脉旁路移植手术的患者中明显未得到充分使用。此外,治疗医生的专业以及医院的状况常常会影响抗血小板治疗的使用。医生对抗血小板药物处方不足的原因尚不完全清楚,但可能与缺乏对指南的熟悉和理解以及药物新颖性、安全性和成本等因素有关。因此,无论是在早期住院阶段还是在患者向社区护理过渡时,持续教育和数据传播对于促进指南推荐药物的处方开具都至关重要。药剂师的作用对于通过与医生和患者互动来确保遵循临床指南至关重要。